RA PHARMCTL INC (NASDAQ:RARX) had its price objective boosted by equities research analysts at Credit Suisse Group from $19.00 to $23.00 in a note issued to investors on Friday. The brokerage currently has an “outperform” rating on the stock. Credit Suisse Group’s target price indicates a potential upside of 62.77% from the stock’s previous close.

Several other analysts also recently weighed in on RARX. Jefferies Group LLC reiterated a “buy” rating and set a $25.00 target price on shares of RA PHARMCTL INC in a research report on Friday, July 14th. Zacks Investment Research downgraded RA PHARMCTL INC from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Finally, Royal Bank Of Canada initiated coverage on RA PHARMCTL INC in a report on Thursday, September 14th. They issued an “outperform” rating and a $21.00 price objective for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $24.67.

RA PHARMCTL INC (RARX) traded up $1.46 during trading hours on Friday, hitting $14.13. The stock had a trading volume of 157,700 shares, compared to its average volume of 158,643. RA PHARMCTL INC has a fifty-two week low of $11.20 and a fifty-two week high of $27.84.

RA PHARMCTL INC (NASDAQ:RARX) last released its earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.06). equities research analysts predict that RA PHARMCTL INC will post -2.54 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.dailypolitical.com/2017/11/12/ra-pharmctl-inc-rarx-pt-raised-to-23-00-at-credit-suisse-group.html.

Several hedge funds have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company raised its holdings in shares of RA PHARMCTL INC by 30.6% in the second quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock valued at $204,000 after acquiring an additional 2,543 shares in the last quarter. TIAA CREF Investment Management LLC raised its holdings in shares of RA PHARMCTL INC by 97.0% in the first quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock valued at $167,000 after acquiring an additional 3,859 shares in the last quarter. California State Teachers Retirement System raised its holdings in shares of RA PHARMCTL INC by 26.1% in the second quarter. California State Teachers Retirement System now owns 20,800 shares of the company’s stock valued at $390,000 after acquiring an additional 4,300 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of RA PHARMCTL INC by 7.0% in the second quarter. Goldman Sachs Group Inc. now owns 73,103 shares of the company’s stock valued at $1,370,000 after acquiring an additional 4,751 shares in the last quarter. Finally, American International Group Inc. bought a new stake in shares of RA PHARMCTL INC in the first quarter valued at about $102,000. Hedge funds and other institutional investors own 66.80% of the company’s stock.

RA PHARMCTL INC Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Analyst Recommendations for RA PHARMCTL INC (NASDAQ:RARX)

Receive News & Ratings for RA PHARMCTL INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RA PHARMCTL INC and related companies with MarketBeat.com's FREE daily email newsletter.